Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article
- 1 September 2022
- journal article
- review article
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (1) , 122-127
Abstract
Ki67 index is considered to be a reliable indicator of the proliferative activity of breast cancer. Additionally, the Ki67 proliferative marker may play a role in assessing response to systemic therapeutic strategies and can act as a prognostic biomarker. But its limited reproducibility which stems from a lack of standardization of procedures, inter-observer variability, and preanalytical and analytical variabilities all have hampered the use of the Ki67 index in clinical practice. Currently, clinical trials have been evaluating Ki67 as a predictive marker for needing adjuvant chemotherapy in luminal early breast cancer patients receiving neoadjuvant endocrine therapy. But the inconsistencies existing in the estimation of the Ki67 index limit the utility of Ki67 in standard clinical practice. The purpose of this review is to evaluate the benefits and drawbacks of utilizing Ki-67 in early-stage breast cancer to prognosticate the disease and predict the risk of recurrence.Keywords
This publication has 34 references indexed in Scilit:
- Breast cancer intrinsic subtype classification, clinical use and future trends.2015
- The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2-invasive breast cancer2015
- Ki67 is a promising molecular target in the diagnosis of cancer (Review)Molecular Medicine Reports, 2014
- Biological subtypes of breast cancer: Prognostic and therapeutic implicationsWorld Journal of Clinical Oncology, 2014
- An International Ki67 Reproducibility StudyJNCI: Journal of the National Cancer Institute, 2013
- Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysisEuropean Journal of Cancer, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and SurvivalClinical Medicine & Research, 2009
- Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and SurvivalClinical Medicine & Research, 2009
- Short-Term Changes in Ki-67 during Neoadjuvant Treatment of Primary Breast Cancer with Anastrozole or Tamoxifen Alone or Combined Correlate with Recurrence-Free SurvivalClinical Cancer Research, 2005